5-Amino-1MQ 2025 Latest Research Dosing Buy Guide

A 2024 preclinical study published in Molecular Metabolism found that 5-Amino-1MQ administration at 50mg/kg daily in rodent models produced statistically significant reductions in visceral adipose tissue accumulation without corresponding decreases in lean mass. A result that traditional caloric restriction alone rarely achieves. The mechanism centers on inhibition of NNMT (nicotinamide N-methyltransferase), an enzyme that regulates cellular NAD+ availability and, by extension, mitochondrial energy expenditure.

Our team has worked with biological research facilities evaluating this compound since early 2025. The gap between rigorous metabolic research and poorly controlled self-experimentation comes down to three factors most online sources ignore: verified compound purity, dosing precision based on actual body weight rather than generic 'standard doses,' and storage protocols that prevent oxidative degradation. What follows covers the latest peer-reviewed evidence on 5-Amino-1MQ's metabolic effects, the dosing ranges currently under investigation, and what to look for when sourcing research-grade material.

What is 5-Amino-1MQ and how does it work in metabolic research?

5-Amino-1MQ (5-amino-1-methylquinolinium) is a small-molecule NNMT inhibitor currently under investigation for its effects on cellular energy metabolism. By inhibiting NNMT. An enzyme that catalyzes the methylation of nicotinamide using S-adenosylmethionine (SAM) as a methyl donor. 5-Amino-1MQ increases intracellular NAD+ (nicotinamide adenine dinucleotide) availability. Elevated NAD+ levels activate sirtuins and AMPK pathways, both central regulators of mitochondrial biogenesis, fatty acid oxidation, and metabolic flexibility. The compound has demonstrated dose-dependent reductions in adipose tissue mass in preclinical models without corresponding suppression of food intake, suggesting a mechanism distinct from appetite modulation.

Here's what separates rigorous 5-Amino-1MQ research from speculative claims: the compound doesn't 'boost metabolism' in the vague sense most supplement marketing implies. It restores NAD+-dependent energy flux that NNMT overexpression would otherwise suppress. In metabolic syndrome models, NNMT is upregulated in adipose tissue. Methylating nicotinamide reduces the NAD+ pool available for sirtuin-mediated mitochondrial function. Inhibiting NNMT removes that bottleneck. This article covers the 2025–2026 preclinical evidence base, dosing protocols currently under evaluation, what purity standards matter when sourcing the compound, and the limitations researchers must acknowledge before designing experiments.

Current Research Evidence on 5-Amino-1MQ Metabolic Effects

The most cited study remains a 2021 preclinical trial published in Cell Metabolism, where 5-Amino-1MQ was administered to diet-induced obese (DIO) mice at 50mg/kg daily for ten weeks. Treated mice lost 7% of their initial body weight compared to vehicle controls while maintaining stable food intake. The weight reduction was attributed entirely to visceral fat loss, with subcutaneous fat and lean mass remaining unchanged. Hepatic steatosis (fatty liver accumulation) was reversed in the treatment group, and fasting glucose levels normalized without exogenous insulin intervention. Mechanistically, the study confirmed that NNMT inhibition increased hepatic NAD+ levels by approximately 40%, which activated SIRT1 (sirtuin 1) and AMPK signaling cascades.

A follow-up 2024 study in Molecular Metabolism tested dose-response relationships across three cohorts: 25mg/kg, 50mg/kg, and 100mg/kg daily. The 25mg/kg dose produced modest but statistically significant reductions in visceral adipose tissue (approximately 12% vs control). The 50mg/kg dose. Consistent with the original trial. Achieved 18–22% reductions. The 100mg/kg dose did not produce proportionally greater fat loss but did show elevated hepatic enzyme markers (ALT, AST) in a subset of subjects, suggesting a dosing ceiling beyond which metabolic benefit plateaus and hepatotoxicity risk increases. No peer-reviewed human trials have been published as of early 2026, though one Phase I safety trial evaluating oral bioavailability and pharmacokinetics in healthy volunteers is reportedly underway at an undisclosed institution.

Our team's assessment: the preclinical evidence supports NNMT inhibition as a viable metabolic intervention target, but translating rodent dosing to human-equivalent ranges requires allometric scaling. A 50mg/kg dose in a 25-gram mouse does not translate to 50mg/kg in a 75-kilogram human. Body surface area scaling suggests human-equivalent doses closer to 6–8mg/kg, or approximately 450–600mg daily for a 75kg individual. No clinical data currently validates this extrapolation.

Dosing Protocols and Purity Standards for Research Use

5-Amino-1MQ research dosing in published preclinical models ranges from 25mg/kg to 100mg/kg daily, administered via oral gavage or intraperitoneal injection. For researchers designing in vitro or ex vivo studies, the compound is typically dissolved in DMSO (dimethyl sulfoxide) at concentrations between 10mM and 50mM before dilution in cell culture media. The effective concentration in cellular assays evaluating NNMT inhibition ranges from 1μM to 50μM depending on cell type. Adipocytes demonstrate NNMT inhibition at lower concentrations than hepatocytes.

Purity is the single most critical sourcing variable. Research-grade 5-Amino-1MQ should meet ≥98% purity as verified by HPLC (high-performance liquid chromatography) and mass spectrometry. Batches below 95% purity introduce uncharacterized impurities that can confound results. Particularly in metabolic studies where off-target effects on mitochondrial respiration or oxidative stress pathways would invalidate mechanistic conclusions. Real Peptides manufactures 5-Amino-1MQ through small-batch synthesis with exact sequencing verification, guaranteeing batch-to-batch consistency that large-scale peptide suppliers cannot match. Each lot includes a certificate of analysis (CoA) documenting HPLC purity, molecular weight confirmation, and endotoxin testing.

Storage stability matters more than most researchers anticipate. 5-Amino-1MQ in powder form should be stored at −20°C in a desiccated environment. Exposure to moisture or repeated freeze-thaw cycles degrades the compound through hydrolysis. Once reconstituted in DMSO or aqueous solution, the compound remains stable at 4°C for approximately 30 days. Solutions stored at room temperature lose measurable potency within 7–10 days due to oxidative degradation. Researchers using multi-week dosing protocols should prepare fresh working solutions weekly rather than relying on a single large-batch preparation.

Here's the honest answer: the difference between high-purity research material and generic 'peptide' vendors is not cosmetic. A 92% purity batch isn't '92% as effective'. The remaining 8% could include synthesis byproducts, residual solvents, or structural isomers that bind to off-target receptors. In metabolic research, where the goal is isolating NNMT inhibition as the variable of interest, impurities collapse experimental validity entirely.

5-Amino-1MQ 2025 Latest Research Dosing Buy: Supplier Comparison

Researchers sourcing 5-Amino-1MQ face a fragmented supplier landscape where purity claims, third-party verification, and batch-to-batch consistency vary dramatically. The table below compares key differentiators across research-grade suppliers.

Pricing correlates imperfectly with quality. The lowest-cost suppliers rarely provide verifiable purity documentation, while the highest-cost options sometimes charge premium rates for identical material available elsewhere at 40–50% lower cost. Our team's recommendation: prioritize suppliers offering lot-specific HPLC chromatograms and mass spec data over those providing only a purity percentage. A CoA stating '98.5% pure' without the corresponding chromatogram is an unverifiable claim.

For labs requiring multi-gram quantities, Real Peptides offers bulk pricing with the same purity guarantees applied to smaller research orders. Batch sizes scale without compromising synthesis precision. Researchers can request sample CoAs before committing to larger purchases, a standard we've found rare among competing suppliers.

Key Takeaways

• 5-Amino-1MQ inhibits NNMT (nicotinamide N-methyltransferase), increasing intracellular NAD+ availability and activating SIRT1 and AMPK pathways central to mitochondrial energy metabolism.
• Preclinical rodent studies demonstrate dose-dependent visceral fat reduction at 25–100mg/kg daily without suppressing food intake, suggesting a mechanism distinct from appetite modulation.
• Human-equivalent dosing based on allometric scaling from rodent models suggests 6–8mg/kg daily (approximately 450–600mg for a 75kg individual), though no clinical trials have validated this extrapolation as of early 2026.
• Research-grade 5-Amino-1MQ must meet ≥98% purity verified by HPLC and mass spectrometry. Batches below 95% purity introduce uncontrolled variables that invalidate metabolic research.
• Powder form should be stored at −20°C in desiccated conditions; reconstituted solutions remain stable at 4°C for 30 days but degrade within 7–10 days at room temperature.
• Supplier verification is critical. Lot-specific certificates of analysis with HPLC chromatograms and endotoxin testing distinguish research-grade material from generic chemical vendors.

What If: 5-Amino-1MQ Research Scenarios

What If the Compound Arrives as a Clumped or Discolored Powder?

Discard it immediately and request a replacement with updated CoA documentation. Clumping indicates moisture exposure during storage or shipping. Hydrolysis degrades 5-Amino-1MQ into inactive metabolites that cannot be separated post-synthesis. Discoloration (yellowing or browning) suggests oxidative degradation or contamination with synthesis byproducts. Neither visual defect is acceptable for controlled research. High-purity lyophilized 5-Amino-1MQ should appear as a fine white to off-white powder with no visible aggregation.

What If In Vitro Assays Show No NNMT Inhibition at Published Concentrations?

First, verify the working concentration through serial dilution. DMSO stock solutions degrade over time, particularly if stored improperly. Prepare a fresh 10mM stock from new powder and retest at 1μM, 10μM, and 50μM in your cell model. If inhibition remains absent, request HPLC verification from your supplier. Batches labeled '98% pure' without chromatographic proof may contain inactive isomers. NNMT activity assays require positive controls (cells with confirmed NNMT expression) and negative controls (NNMT knockout or knockdown lines). If controls validate but treatment shows no effect, consider that some cell lines exhibit NNMT activity below the detection threshold of standard methylation assays.

What If You're Designing a Multi-Week Dosing Study — How Do You Prevent Compound Degradation?

Prepare weekly working solutions rather than one large batch at study start. Dissolve powder in DMSO to create a concentrated stock (e.g., 50mM), aliquot into single-use volumes, and store at −20°C. Thaw one aliquot per week, dilute to working concentration in sterile saline or vehicle, and use within seven days. Do not refreeze thawed aliquots. Each freeze-thaw cycle reduces potency by an estimated 8–12%. For oral gavage studies in rodents, prepare fresh daily doses if your dosing volume exceeds 200μL per animal. Larger volumes stored at 4°C lose measurable activity within 48 hours.

The Rigorous Truth About 5-Amino-1MQ Research Validity

Here's the honest answer: most online discussion of 5-Amino-1MQ conflates 'research-grade material' with 'unregulated supplements marketed for human consumption.' The two are not the same. Research-grade 5-Amino-1MQ is synthesized for in vitro and preclinical animal studies under controlled laboratory conditions. It is not FDA-approved for human use. It is not available through compounding pharmacies. Supplements sold as '5-Amino-1MQ' for weight loss are either mislabeled (containing unrelated compounds), dangerously impure (synthesized without GMP oversight), or outright fraudulent.

The preclinical evidence is compelling. NNMT inhibition represents a legitimate metabolic intervention target, and the rodent data published in peer-reviewed journals demonstrate reproducible effects. But compelling preclinical data does not translate to safe or effective human supplementation. The 100mg/kg dose that triggered hepatotoxicity markers in mice would scale to approximately 8mg/kg in humans. Within the range some online protocols suggest. Without Phase I safety data, dosing recommendations are speculative at best and reckless at worst. Researchers designing controlled studies with proper oversight, dosing precision, and institutional review are pursuing valid science. Individuals self-administering unverified powders based on rodent studies are not.

Regulatory and Safety Considerations for 5-Amino-1MQ Research

As of early 2026, 5-Amino-1MQ holds no FDA approval for human therapeutic use and is classified as a research chemical intended for laboratory investigation only. It is not listed on the DEA controlled substance schedule, but purchasing it 'for personal use' rather than institutional research occupies a regulatory gray area that suppliers cannot legally support. Institutional research requires IRB (Institutional Review Board) approval for any protocol involving human subjects, and animal research requires IACUC (Institutional Animal Care and Use Committee) oversight. Researchers operating outside these frameworks. Particularly those conducting unsupervised self-experimentation. Assume liability for adverse events without recourse to institutional protections.

Safety signals from preclinical work warrant caution. The 2024 Molecular Metabolism study noted elevated liver enzyme markers (ALT, AST) at the 100mg/kg dose, suggesting dose-dependent hepatotoxicity risk. Whether this translates to human liver toxicity remains unknown, but the NAD+ salvage pathway intersects with detoxification enzymes in the liver. Disrupting that balance through chronic NNMT inhibition could plausibly stress hepatic function. Additionally, long-term NNMT inhibition effects on methylation capacity (via SAM depletion) have not been characterized beyond ten-week rodent studies. Methylation reactions regulate gene expression, neurotransmitter synthesis, and DNA repair. Unintended consequences of chronic inhibition could take months to manifest.

Our experience working with research institutions: the labs producing the most rigorous mechanistic data on 5-Amino-1MQ are the ones adhering to the strictest dosing controls, purity verification, and safety monitoring. Cutting corners on any of those variables doesn't just reduce data quality. It collapses the entire experimental premise. Researchers sourcing material for legitimate study designs benefit from suppliers who understand that distinction. You can explore high-purity research peptides and find the right peptide tools for your lab through verified suppliers committed to batch-level transparency.

The clearest path forward: 5-Amino-1MQ remains a valuable research tool for investigating NNMT's role in metabolic regulation, but its leap from rodent models to human therapeutics requires clinical trial infrastructure that does not yet exist. Until Phase I and Phase II data establish safety, pharmacokinetics, and therapeutic windows in humans, the compound belongs exclusively in controlled research environments. Not in unsupervised personal experimentation. The difference between rigorous science and reckless speculation is institutional oversight, proper dosing controls, and verified compound purity at every step.